Alex P Hoyle1, Adnan Ali2, Nicholas D James3, Adrian Cook4, Christopher C Parker5, Johann S de Bono5, Gerhardt Attard6, Simon Chowdhury7, William R Cross8, David P Dearnaley9, Christopher D Brawley4, Clare Gilson4, Fiona Ingleby5, Silke Gillessen10, Daniel M Aebersold11, Rob J Jones12, David Matheson13, Robin Millman14, Malcolm D Mason15, Alastair W S Ritchie5, Martin Russell12, Hassan Douis3, Mahesh K B Parmar4, Matthew R Sydes4, Noel W Clarke16. 1. The Christie and Royal Salford Hospitals, Manchester, UK; Genito Urinary Cancer Research Group and the FASTMAN Centre of Excellence, Division of Cancer Sciences, The University of Manchester, Manchester, UK. 2. The Christie and Royal Salford Hospitals, Manchester, UK. 3. Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, UK. 4. MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK. 5. Royal Marsden Hospital, Sutton, UK. 6. UCL Cancer Institute, University College London, London, UK. 7. Guy's & St Thomas NHS Foundation Trust, London, UK. 8. St James University Hospital, Leeds, UK. 9. Institute of Cancer Research, Sutton, UK. 10. Division of Oncology and Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland; Christie Hospital, Manchester, UK; University of Manchester, Manchester, UK; Swiss Group for Cancer Clinical Research (SAKK), Bern, Switzerland. 11. Department of Radiation Oncology, Bern University Hospital, Switzerland. 12. Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK. 13. Northampton, UK. 14. Stockton-on-Tees, UK. 15. University of Cardiff, Cardiff, UK. 16. The Christie and Royal Salford Hospitals, Manchester, UK; Genito Urinary Cancer Research Group and the FASTMAN Centre of Excellence, Division of Cancer Sciences, The University of Manchester, Manchester, UK. Electronic address: noel.clarke@christie.nhs.uk.
Abstract
BACKGROUND: Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the STAMPEDE trial. There remains uncertainty as to whether men with LATITUDE "low-risk" M1 disease benefit from androgen deprivation therapy (ADT) combined with abiraterone acetate and prednisolone (AAP). OBJECTIVE: Evaluation of heterogeneity of effect between LATITUDE high- and low-risk M1 prostate cancer patients receiving ADT + AAP in the STAMPEDE trial. DESIGN, SETTING, AND PARTICIPANTS: A post hoc subgroup analysis of the 2017 STAMPEDE "abiraterone comparison". Staging scans for M1 patients contemporaneously randomised to ADT or ADT + AAP within the STAMPEDE trial were evaluated centrally and blind to treatment assignment. Stratification was by risk according to the criteria set out in the LATITUDE trial. Exploratory subgroup stratification incorporated the CHAARTED criteria. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome measure was overall survival (OS) and the secondary outcome measure was failure-free survival (FFS). Further exploratory analysis evaluated clinical skeletal-related events, progression-free survival (PFS), and prostate cancer-specific death. Standard Cox-regression and Kaplan-Meier survival estimates were employed for analysis. RESULTS AND LIMITATIONS: A total of 901 M1 STAMPEDE patients were evaluated after exclusions. Of the patients, 428 (48%) were identified as having a low risk and 473 (52%) a high risk. Patients receiving ADT + AAP had significantly improved OS (low-risk hazard ratio [HR]: 0.66, 95% confidence interval or CI [0.44-0.98]) and FFS (low-risk HR: 0.24, 95% CI [0.17-0.33]) compared with ADT alone. Heterogeneity of effect was not seen between low- and high-risk groups for OS or FFS. For OS benefit in low risk, the number needed to treat was four times greater than that for high risk. However, this was not observed for the other measured endpoints. CONCLUSIONS: Men with mHNPC gain treatment benefit from ADT + AAP irrespective of risk stratification for "risk" or "volume". PATIENT SUMMARY: Coadministration of abiraterone acetate and prednisolone with androgen deprivation therapy (ADT) is associated with prolonged overall survival and disease control, compared with ADT alone, in all men with metastatic disease starting hormone therapy for the first time.
BACKGROUND: Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the STAMPEDE trial. There remains uncertainty as to whether men with LATITUDE "low-risk" M1 disease benefit from androgen deprivation therapy (ADT) combined with abiraterone acetate and prednisolone (AAP). OBJECTIVE: Evaluation of heterogeneity of effect between LATITUDE high- and low-risk M1 prostate cancer patients receiving ADT + AAP in the STAMPEDE trial. DESIGN, SETTING, AND PARTICIPANTS: A post hoc subgroup analysis of the 2017 STAMPEDE "abiraterone comparison". Staging scans for M1 patients contemporaneously randomised to ADT or ADT + AAP within the STAMPEDE trial were evaluated centrally and blind to treatment assignment. Stratification was by risk according to the criteria set out in the LATITUDE trial. Exploratory subgroup stratification incorporated the CHAARTED criteria. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome measure was overall survival (OS) and the secondary outcome measure was failure-free survival (FFS). Further exploratory analysis evaluated clinical skeletal-related events, progression-free survival (PFS), and prostate cancer-specific death. Standard Cox-regression and Kaplan-Meier survival estimates were employed for analysis. RESULTS AND LIMITATIONS: A total of 901 M1 STAMPEDE patients were evaluated after exclusions. Of the patients, 428 (48%) were identified as having a low risk and 473 (52%) a high risk. Patients receiving ADT + AAP had significantly improved OS (low-risk hazard ratio [HR]: 0.66, 95% confidence interval or CI [0.44-0.98]) and FFS (low-risk HR: 0.24, 95% CI [0.17-0.33]) compared with ADT alone. Heterogeneity of effect was not seen between low- and high-risk groups for OS or FFS. For OS benefit in low risk, the number needed to treat was four times greater than that for high risk. However, this was not observed for the other measured endpoints. CONCLUSIONS: Men with mHNPC gain treatment benefit from ADT + AAP irrespective of risk stratification for "risk" or "volume". PATIENT SUMMARY: Coadministration of abiraterone acetate and prednisolone with androgen deprivation therapy (ADT) is associated with prolonged overall survival and disease control, compared with ADT alone, in all men with metastatic disease starting hormone therapy for the first time.
Authors: Alan I So; Kim N Chi; Brita Danielson; Neil E Fleshner; Anil Kapoor; Tamim Niazi; Frederic Pouliot; Ricardo A Rendon; Bobby Shayegan; Srikala Sridhar; Eric Vigneault; Fred Saad Journal: Can Urol Assoc J Date: 2019-12-05 Impact factor: 1.862
Authors: Scott Wilkinson; Huihui Ye; Fatima Karzai; Stephanie A Harmon; Nicholas T Terrigino; David J VanderWeele; John R Bright; Rayann Atway; Shana Y Trostel; Nicole V Carrabba; Nichelle C Whitlock; Stephanie M Walker; Rosina T Lis; Houssein Abdul Sater; Brian J Capaldo; Ravi A Madan; James L Gulley; Guinevere Chun; Maria J Merino; Peter A Pinto; Daniela C Salles; Harsimar B Kaur; Tamara L Lotan; David J Venzon; Peter L Choyke; Baris Turkbey; William L Dahut; Adam G Sowalsky Journal: Eur Urol Date: 2021-03-27 Impact factor: 20.096
Authors: Lin Wang; Channing Paller; Hwanhee Hong; Lori Rosman; Anthony De Felice; Otis Brawley; G Caleb Alexander Journal: J Natl Cancer Inst Date: 2022-02-07 Impact factor: 13.506
Authors: Richard J Rebello; Christoph Oing; Karen E Knudsen; Stacy Loeb; David C Johnson; Robert E Reiter; Silke Gillessen; Theodorus Van der Kwast; Robert G Bristow Journal: Nat Rev Dis Primers Date: 2021-02-04 Impact factor: 52.329